Literature DB >> 28559287

Occult myeloproliferative neoplasms: not so occult any more.

Dhauna Karam1, Veena Iyer2, Bharat Agrawal2.   

Abstract

Non-cirrhotic, non-malignant portal vein thrombosis (PVT) is commonly secondary to inherited or acquired prothrombotic states. However, even after extensive workup, 25% of patients with PVT have no apparent prothrombotic aetiology identified (idiopathic PVT). Inherited conditions include factor V Leiden, PT mutation and protein C/S/AT deficiency. Acquired conditions include APS, PNH and BCR-ABL 1-negative myeloproliferative neoplasms (MPN). BCR-ABL-1 negative MPNs are the most frequent underlying prothrombotic risk factor for PVT (15%-30%). However, peripheral blood counts often remain within normal ranges in these patients with MPN because of portal hypertension sequel. Despite suggestive features of MPN in bone marrow, these patients lack adequate diagnostic criteria and are classified as occult MPN. The discovery of recurrent molecular abnormalities such as CALR gene exon 9 mutation presented a crucial advance in the diagnosis of occult MPNs. In our patient, the diagnosis of MPN was made on this basis, despite lack of peripheral evidence of MPN. © BMJ Publishing Group Ltd (unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  haematology (incl blood transfusion); medical management

Mesh:

Substances:

Year:  2017        PMID: 28559287      PMCID: PMC5747619          DOI: 10.1136/bcr-2017-219388

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  12 in total

Review 1.  The myeloproliferative disorders.

Authors:  Peter J Campbell; Anthony R Green
Journal:  N Engl J Med       Date:  2006-12-07       Impact factor: 91.245

2.  Meta-analysis: the significance of screening for JAK2V617F mutation in Budd-Chiari syndrome and portal venous system thrombosis.

Authors:  X Qi; Z Yang; M Bai; X Shi; G Han; D Fan
Journal:  Aliment Pharmacol Ther       Date:  2011-03-13       Impact factor: 8.171

3.  A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.

Authors:  Chloé James; Valérie Ugo; Jean-Pierre Le Couédic; Judith Staerk; François Delhommeau; Catherine Lacout; Loïc Garçon; Hana Raslova; Roland Berger; Annelise Bennaceur-Griscelli; Jean Luc Villeval; Stefan N Constantinescu; Nicole Casadevall; William Vainchenker
Journal:  Nature       Date:  2005-04-28       Impact factor: 49.962

4.  Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.

Authors:  E Joanna Baxter; Linda M Scott; Peter J Campbell; Clare East; Nasios Fourouclas; Soheila Swanton; George S Vassiliou; Anthony J Bench; Elaine M Boyd; Natasha Curtin; Mike A Scott; Wendy N Erber; Anthony R Green
Journal:  Lancet       Date:  2005 Mar 19-25       Impact factor: 79.321

5.  Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome.

Authors:  Raj K Patel; Nicholas C Lea; Michael A Heneghan; Nigel B Westwood; Dragana Milojkovic; Murugaiyan Thanigaikumar; Deborah Yallop; Roopen Arya; Antonio Pagliuca; Joop Gäken; Julia Wendon; Nigel D Heaton; Ghulam J Mufti
Journal:  Gastroenterology       Date:  2006-06       Impact factor: 22.682

6.  Somatic mutations of calreticulin in myeloproliferative neoplasms.

Authors:  Thorsten Klampfl; Heinz Gisslinger; Ashot S Harutyunyan; Harini Nivarthi; Elisa Rumi; Jelena D Milosevic; Nicole C C Them; Tiina Berg; Bettina Gisslinger; Daniela Pietra; Doris Chen; Gregory I Vladimer; Klaudia Bagienski; Chiara Milanesi; Ilaria Carola Casetti; Emanuela Sant'Antonio; Virginia Ferretti; Chiara Elena; Fiorella Schischlik; Ciara Cleary; Melanie Six; Martin Schalling; Andreas Schönegger; Christoph Bock; Luca Malcovati; Cristiana Pascutto; Giulio Superti-Furga; Mario Cazzola; Robert Kralovics
Journal:  N Engl J Med       Date:  2013-12-10       Impact factor: 91.245

7.  JAK2V617F mutation in patients with portal vein thrombosis.

Authors:  Yusuf Bayraktar; Ozgur Harmanci; Yahya Büyükasik; Ali Ibrahim Shorbagi; Aysegul Hasegeli Sungur; Cemaliye Akyerli Boylu; Aytemiz Gürgey; Ferhun Balkanci
Journal:  Dig Dis Sci       Date:  2008-03-15       Impact factor: 3.199

Review 8.  Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis.

Authors:  Jasper H Smalberg; Lidia R Arends; Dominique C Valla; Jean-Jacques Kiladjian; Harry L A Janssen; Frank W G Leebeek
Journal:  Blood       Date:  2012-10-04       Impact factor: 22.113

9.  Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia.

Authors:  Giada Rotunno; Carmela Mannarelli; Paola Guglielmelli; Annalisa Pacilli; Alessandro Pancrazzi; Lisa Pieri; Tiziana Fanelli; Alberto Bosi; Alessandro M Vannucchi
Journal:  Blood       Date:  2013-12-26       Impact factor: 22.113

10.  Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2.

Authors:  J Nangalia; C E Massie; E J Baxter; F L Nice; G Gundem; D C Wedge; E Avezov; J Li; K Kollmann; D G Kent; A Aziz; A L Godfrey; J Hinton; I Martincorena; P Van Loo; A V Jones; P Guglielmelli; P Tarpey; H P Harding; J D Fitzpatrick; C T Goudie; C A Ortmann; S J Loughran; K Raine; D R Jones; A P Butler; J W Teague; S O'Meara; S McLaren; M Bianchi; Y Silber; D Dimitropoulou; D Bloxham; L Mudie; M Maddison; B Robinson; C Keohane; C Maclean; K Hill; K Orchard; S Tauro; M-Q Du; M Greaves; D Bowen; B J P Huntly; C N Harrison; N C P Cross; D Ron; A M Vannucchi; E Papaemmanuil; P J Campbell; A R Green
Journal:  N Engl J Med       Date:  2013-12-10       Impact factor: 91.245

View more
  1 in total

1.  Detecting CALR Mutations in Splanchnic Vein Thrombosis: Who and How?

Authors:  Stephen E Langabeer
Journal:  J Transl Int Med       Date:  2018-06-26
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.